Bristol Myers Squibb’s experimental psoriasis drug deucravacitinib (BMS-986165) beat out Amgen’s Otezla (apremilast) in the POETYK PSO-1 Phase III clinical trial.

Dermavant Sciences announced positive data from two Phase III clinical trials evaluating tapinarof cream 1% in adults with plaque psoriasis.

The U.S. Food and Drug Administration approved MC2 Therapeutics’ Wynzora Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) for once-daily topical treatment of plaque psoriasis in adults 18 years of age or older.

Eli Lilly’s experimental treatment mirikizumab for plaque psoriasis beat out Novartis’ vaunted drug Cosentyx in a Phase III comparison study.

Equillium partner Biocon reported data from a clinical trial showing that itolizumab significantly decreased mortality in hospitalized COVID-19 patients.

AbbVie reported that the company’s drug Skyrizi met both primary and all ranked secondary endpoints in a Phase III trial that went head-to-head with Novartis’ Cosentyx in plaque psoriasis.

Shares of Durect Corporation plunged more than 31 percent after the company announced the Phase IIa plaque psoriasis treatment sulfated oxysterol failed to distinguish itself against placebo.

UCB SA said the company’s experimental plaque psoriasis drug bimekizumab produced better results compared to AbbVie Inc.’s blockbuster medicine Humira in reducing the disease’s severity.

China’s Bio-Thera Solutions Ltd. won a regulatory approval for the company’s version of AbbVie Inc.’s blockbuster rheumatoid arthritis treatment Humira, paving the way for the first such biosimilar to enter the world’s second-largest drug market.

J&J’s Janssen Pharmaceutical released new long-term data from the open-label period of the Phase III VOYAGE 1 study.